(Q34875099)

5 August 2017

1 reference

title

Beyond lipid lowering: the role of statins in vascular protection (English)

1 reference

5 August 2017

James K Liao

1

1 reference

5 August 2017

language of work or name

1 reference

1 November 2002

1 reference

International Journal of Cardiology

5 August 2017

published in

1 reference

5 August 2017

volume

86

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

5-18

1 reference

The future of best practice

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Low-density lipoprotein-independent effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Direct vascular effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The evolving role of statins in the management of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Pleiotropic effects of statins and their clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Stimulation of bone formation in vitro and in rodents by statins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

HMG-CoA reductase inhibitors and the risk of fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Cholesterol lowering and endothelial function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Induction of chemotactic cytokines by minimally oxidized LDL.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Chemokines and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Molecular bases of the acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Cholesterol reduction yields clinical benefit: impact of statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Lipid-lowering therapy in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Endothelial dysfunction: clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Assessment and treatment of endothelial dysfunction in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Is measurement of endothelial dysfunction clinically useful?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Neuroprotection mediated by changes in the endothelial actin cytoskeleton.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Rho GTPases and signaling networks

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Changing concepts of atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Mechanisms of NADPH oxidase activation in human neutrophils: p67phox is required for the translocation of rac 1 but not of rac 2 from cytosol to the membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Rac1 disrupts p67phox/p40phox binding: a novel role for Rac in NADPH oxidase activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Isolation of putative progenitor endothelial cells for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Statins do more than just lower cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inflammation, atherosclerosis, and ischemic events -- exploring the hidden side of the moon.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Coronary C-reactive protein distribution: its relation to development of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Processes in atherogenesis: complement activation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inhibition of proinflammatory cytokine production by pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Cell cycle progression: new therapeutic target for vascular proliferative disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

PROAPOPTOTIC EFFECT OF ATORVASTATIN ON STIMULATED RABBIT SMOOTH MUSCLE CELLS

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Pro-apoptotic effect of fluvastatin on human smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Platelet activation in unstable coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Are we mortgaging the medical profession?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Platelet alpha 2-adrenergic receptors in hypercholesterolemia: relationship between binding studies and epinephrine-induced platelet aggregation.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Platelet Deposition on Eroded Vessel Walls at a Stenotic Shear Rate Is Inhibited by Lipid-Lowering Treatment With Atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Structural mechanism for statin inhibition of HMG-CoA reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

The endotoxin-lipoprotein hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2802%2900195-X

7 January 2021

10.1016/S0167-5273(02)00195-X

Identifiers

DOI

1 reference

5 August 2017

1 reference